Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Consumer Defensive · Tobacco

Philip Morris International logoPhilip Morris International

PM · a US exchange · USD · Market cap $301.0B · 84,900 employees

Philip Morris International Inc.

FAIL · Does not pass the screen
194.38 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price194.38 USD at the 17 Nov 2026 close
  • Our value readFair vs our fair value, as of 17 Nov 2026
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans heavily to calls (put/call 0.50)
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $157.50 to $230.49, base estimate $200.42 (screen dated 2026-11-17).

Current read
Distribution ?
Fair · screened 2026-11-17
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 0.50, read 2026-11-13
  • Ethical does not pass the values gate
Price194.38 USD
Fair value200.42
Ethical score10.0/100
Value readFairas of 17 Nov 2026
Our investment reviews on this name
2026-11-11Read Distribution194.25+0.1% to today Markup gives way to Distribution
2026-10-20Read Markup199.90-2.8% to today Accumulation gives way to Markup first Markup read since August
2026-10-02Read Accumulation190.48+2.0% to today ✓Markup gives way to Accumulation after a 7% rise in 13 weeks
2026-07-02Read Markup178.29+9.0% to today ✓First review on file: Markup

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Philip Morris International holds its Distribution at $194.38. Consolidating, no directional conviction, held for 93 days.

As held on the ledger · 2026-11-17
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 93 days
Price at the screen$194.38
Valuation28.19 trailing · 21.36 forward price to earnings
Values screenFAIL · score 10.0
Beta0.35
The Workings

Five Screens, Shown in Full

Does not pass. Business activity screen

TestFigureLimitWhat it meansStatus
Business activity Excluded Core business clean Business activity: Tobacco Fail

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Falls Short, in Plain English

Philip Morris International does not clear the screen at the business-activity stage. It operates in tobacco, so the financial ratios are not the deciding factor here.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when PM's ethical verdict changes

Today PM does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Fair vs our fair value, as of 17 Nov 2026: it trades at roughly a 3% discount to our $200.42 fair value, 5.50% revenue growth.

How a fair value is estimated: discounted cash flow (DCF).

157.50Conservative200.42Base case230.49Growth case 194.38Price

Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. A 3.0% discount to the base estimate.

The Street's Range
175.00Street low 220.00Street average 240.00Street high 194.38Price

Third-party analyst targets: 15 covering, consensus Buy. The average target sits +13% from the screen price.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Price History & Projections

Where our models see it going: fair-value estimate $200.42, with a range of $157.50 to $230.49, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Smoking Through the Fog of Ethical Concerns

Imagine lighting up a cigarette, and with each puff, the smoke obscures not just your health but also your ethical vision. That's the conundrum Philip Morris International presents. As a global tobacco giant, it offers a smorgasbord of cigarettes and smoke-free alternatives under brands like IQOS and VEEV. Yet, the company's business activity flunks our ethical screen, a clear red flag in our books.

Despite a forward P/E of 20.9x and a 10% revenue growth, the numbers can't mask the ethical failings. Philip Morris sits at a profit margin of 26%, which might seem like a robust yield, but the market consensus is fragmented with no clear rating and a median target price of $210. The opportunity rating of AVOID is not due to a lack of financial performance, but the ethical smokescreen that surrounds it.

Risks are manifold, with the company's moat being unknown and the ethical failings a significant concern. The market may price it one way, but our ethical-first approach steers us clear from the smoke and mirrors of such businesses. Remember, when the ethical compass points away, it's often wise to follow. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E21.4xexpensive even after accounting for its growth
Trailing P/E28.2xa premium valuation
EPS, trailing6.85
EPS, forward9.04
Revenue growth+5.5%slow but positive growth
Profit margin24.8%healthy profit margins
FCF yield3.83%
Dividend yield3.11%
Current ratio1.02adequate liquidity, worth monitoring
Beta0.35barely tracks the market's swings
Short interest, float0.01%
52-week range146.35 - 214.35
Market cap$301.0B
Employees84,900

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

PM trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-18 Distribution $194.38 +0.1% Entry 23

The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193.

2026-11-11 Distribution · changed $194.25 -6.6% Entry 22

The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 6.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193.

2026-11-04 Markup $208.03 +4.1% Entry 21

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193.

2026-10-28 Markup $199.90 +0.0% Entry 20

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 13% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193.

2026-10-21 Markup $199.90 +0.0% Entry 19

The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-20 Markup · changed $199.90 +0.0% Entry 18

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-19 Accumulation $199.90 +0.0% Entry 17

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 18% above its long-term trend line with momentum reading overbought. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-18 Accumulation $199.90 +0.0% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-17 Accumulation $199.90 +0.0% Entry 15

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-16 Accumulation $199.90 -0.6% Entry 14

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 11% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 6%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (14 analysts) rates it buy, with a mean price target of $193. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on PM

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in PM's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · PM
DateInsiderTitleTypeSharesValue
2026-05-06 CALANTZOPOULOS ANDRE Chairman of the Board 1,119 $190,152
2026-05-06 HARKER VICTORIA D Director 1,119 $190,152
2026-05-06 GEISSLER WERNER Director 1,119 $190,152
2026-05-06 HOOK LISA A. Director 1,119 $190,152
2026-05-06 BOUGH BONIN Director 1,119 $190,152
2026-05-06 COMBES MICHEL Director 1,119 $190,152
2026-05-06 POLET ROBERT Director 1,119 $190,152
2026-05-06 YANAI SHLOMO Director 1,119 $190,152
2026-05-06 MORPARIA KALPANA Director 1,119 $190,152
2026-02-20 DOBROWOLSKI REGINALDO Officer 6,000 $1,100,880

Public filings, recorded as found. The full tape lives at Insider Intelligence.

The Political Ledger · Congressional Disclosures
Disclosures naming PM
DatePoliticianPartyTypeAmount
2026-10-15 David Taylor Republican buy 1K–15K
2026-10-15 David Taylor Republican buy 1K–15K
2026-10-15 Ro Khanna Democrat buy 1K–15K
2026-10-15 David Taylor Republican buy 1K–15K
2026-10-13 Gil Cisneros Democrat sell 50K–100K
What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $182.11 +0.3% · $1,003 +0.3%
2 months $160.45 +13.9% · $1,139 +13.9%
3 months $170.48 +7.2% $1.47 $1,080 +8.0%
6 months $148.26 +23.2% $2.94 $1,252 +25.2%
1 year $172.90 +5.7% $5.76 $1,090 +9.0%
2 years $95.83 +90.7% $11.11 $2,023 +102.3%
3 years $81.02 +125.5% $16.28 $2,456 +145.6%
5 years $77.95 +134.4% $26.29 $2,681 +168.1%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever PM does next, these words stay.

Philip Morris International · PM · Distribution · $194.38
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.